Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Viatris Inc.
483
•Viatris Inc.•April 12, 2018

Viatris Inc. – FDA 483, Apr 12, 2018

Record Details

This FDA Form 483 details observations from an inspection of Mylan Pharmaceuticals Inc., a finished drug product manufacturer located at 781 Chestnut Ridge Rd, Morgantown, WV, conducted from March 19, 2018, to April 12, 2018.

**Key Observations:**

1. **Quality Unit Deficiencies:** The Quality Unit (QU) failed to fully follow its procedures, lacking appropriate oversight in approving change controls and reviewing/approving equipment and facilities. 2. **Process Control Issues (Metolazone 2.5 mg Tablets):** Inadequate process control parameters led to Out-of-Tolerance/Out-of-Specification (OOT/OOS) content uniformity results for Metolazone 2.5 mg Tablets, with multiple Manufacturing Investigation Reports (MIRs) opened and one batch rejected. Corrective and preventive actions (CAPAs) failed to mitigate powder segregation and content uniformity issues. 3. **Unapproved Changes (Doxycycline Hyclate Delayed-release Tablets):** The QU implemented changes to weight and hardness specifications for Doxycycline Hyclate Delayed-release Tablets without adequate evaluation or accelerated stability studies, leading to dissolution profile issues during long-term stability. 4. **Inadequate Cleaning Procedures and Investigation Scope:** Root cause for contamination was identified as inadequate cleaning procedures (MPI-SOP-MFG-ENC-0008) and

Company
Viatris Inc.
Inspection date
April 12, 2018
Product type
Drugs
Office
Baltimore District Office
People
  • Marcus A. Ray (Supervisory Consumer Safety Officer, China Office)
  • Melissa T. Roy (Regulatory Counsel at FDA with a PharmD and JD)
  • Leana Barreto-Pettit (Vice President, Technical)
  • Ko U. Min (Consumer Safety Officer at FDA U.S. Food and Drug Administration)
  • Alison N. Stieg (Staff Director)
View Company Profile

ID · 24a2a7cc-647e-427c-9f53-a9a19e40ec12

Violation Codes1
21 CFR 331(c)

Full citation text and observation details available on the Dashboard.

Other documents for Viatris Inc.
  • WARNING_LETTER - 2024-06-26June 26, 2024
  • 483 - 2022-05-26May 26, 2022
  • 483 - 2019-08-15August 15, 2019
  • 483 - 2019-07-25July 25, 2019
  • 483 - 2016-11-18November 18, 2016

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Viatris Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.